HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents (2024)
- Authors:
- Waitman, Karoline de Barros
- Almeida, Larissa Costa de
- Primi, Marina Candido
- Carlos, Jorge Antonio Elias Godoy
- Ruiz, Claudia
- Kronenberger, Thales
- Laufer, Stefan
- Goettert, Marcia Ines
- Poso, Antti
- Vassiliades, Sandra Valeria
- Souza, Vinicius Albuquerque Moreira de
- Toledo, Mônica Franco Zannini Junqueira
- Hassimotto, Neuza Mariko Aymoto
- Cameron, Michael D
- Bannister, Thomas D
- Costa-Lotufo, Letícia Veras
- Machado Neto, João Agostinho
- Tavares, Maurício T.
- Parise Filho, Roberto
- Waitman, Karoline de Barros
- USP affiliated authors: TOLEDO, MONICA FRANCO ZANNINI JUNQUEIRA - FCF ; HASSIMOTTO, NEUZA MARIKO AYMOTO - FCF ; LOTUFO, LETICIA VERAS COSTA - ICB ; MACHADO NETO, JOÃO AGOSTINHO - ICB ; PARISE FILHO, ROBERTO - FCF ; WAITMAN, KAROLINE DE BARROS - FCF ; ALMEIDA, LARISSA COSTA DE - ICB ; CARLOS, JORGE ANTONIO ELIAS GODOY - ICB ; VASSILIADES, SANDRA VALERIA - FCF
- Unidades: FCF; ICB
- DOI: 10.1016/j.ejmech.2023.115935
- Subjects: ANTINEOPLÁSICOS; HIBRIDIZAÇÃO; CÉLULAS CULTIVADAS DE TUMOR; PROTEÍNAS; PURINAS; CITOTOXINAS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Issy-Les-Moulineaux
- Date published: 2024
- Source:
- Título: European Journal of Medicinal Chemistry
- ISSN: 0223-5234
- Volume/Número/Paginação/Ano: v. 263, p. 1-18 art. 115935, 2024
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
WAITMAN, Karoline de Barros et al. HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents. European Journal of Medicinal Chemistry, v. 263, p. 1-18 art. 115935, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.ejmech.2023.115935. Acesso em: 27 dez. 2025. -
APA
Waitman, K. de B., Almeida, L. C. de, Primi, M. C., Carlos, J. A. E. G., Ruiz, C., Kronenberger, T., et al. (2024). HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents. European Journal of Medicinal Chemistry, 263, 1-18 art. 115935. doi:10.1016/j.ejmech.2023.115935 -
NLM
Waitman K de B, Almeida LC de, Primi MC, Carlos JAEG, Ruiz C, Kronenberger T, Laufer S, Goettert MI, Poso A, Vassiliades SV, Souza VAM de, Toledo MFZJ, Hassimotto NMA, Cameron MD, Bannister TD, Costa-Lotufo LV, Machado Neto JA, Tavares MT, Parise Filho R. HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents [Internet]. European Journal of Medicinal Chemistry. 2024 ; 263 1-18 art. 115935.[citado 2025 dez. 27 ] Available from: https://dx.doi.org/10.1016/j.ejmech.2023.115935 -
Vancouver
Waitman K de B, Almeida LC de, Primi MC, Carlos JAEG, Ruiz C, Kronenberger T, Laufer S, Goettert MI, Poso A, Vassiliades SV, Souza VAM de, Toledo MFZJ, Hassimotto NMA, Cameron MD, Bannister TD, Costa-Lotufo LV, Machado Neto JA, Tavares MT, Parise Filho R. HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents [Internet]. European Journal of Medicinal Chemistry. 2024 ; 263 1-18 art. 115935.[citado 2025 dez. 27 ] Available from: https://dx.doi.org/10.1016/j.ejmech.2023.115935 - Design and synthesis of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment
- Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models
- Design of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment
- Synthesis of 6-arylaminoflavones via buchwald–hartwig amination and Its anti-tumor investigation
- Efficient synthesis of 6-Arylaminoflavones via buchwald-hartwig amination and its anti-tumor Investigation
- Compostos híbridos e usos dos referidos compostos
- Purine-derived Phenylhydroxamate compounds induces cell death in hematological neoplasm models
- Enhancing venetoclax efficacy in leukemia through association with HDAC inhibitors
- Synthesis and biological evaluation of purine-benzohydroxamates as potential inhibitors of PI3K and HDAC6 for the treatment of hematologic malignancies
- Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors
Informações sobre o DOI: 10.1016/j.ejmech.2023.115935 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
3165451.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
